Characteristics of tumour stroma in regional lymph node metastases in colorectal cancer patients: a theoretical framework for future diagnostic imaging with FAPI PET/CT.
Cancer-associated fibroblasts
Colorectal cancer
FAPI
Lymph nodes
Tumour-stroma ratio
Journal
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
ISSN: 1699-3055
Titre abrégé: Clin Transl Oncol
Pays: Italy
ID NLM: 101247119
Informations de publication
Date de publication:
Sep 2022
Sep 2022
Historique:
received:
22
02
2022
accepted:
01
04
2022
pubmed:
29
4
2022
medline:
3
8
2022
entrez:
28
4
2022
Statut:
ppublish
Résumé
The recently developed fibroblast activation protein inhibitor (FAPI) tracer for PET/CT, binding tumour-stromal cancer-associated fibroblasts, is a promising tool for detection of positive lymph nodes. This study provides an overview of features, including sizes and tumour-stromal content, of lymph nodes and their respective lymph node metastases (LNM) in colorectal cancer (CRC), since literature lacks on whether LNMs contain sufficient stroma to potentially allow FAPI-based tumour detection. Haematoxylin and eosin-stained tissue slides from 73 stage III colon cancer patients were included. Diameters and areas of all lymph nodes and their LNMs were assessed, the amount of stroma by measuring the stromal compartment area, the conventional and total tumour-stroma ratios (TSR-c and TSR-t, respectively), as well as correlations between these parameters. Also, subgroup analysis using a minimal diameter cut off of 5.0 mm was performed. In total, 126 lymph nodes were analysed. Although positive correlations were observed between node and LNM for diameter and area (r = 0.852, p < 0.001 and r = 0.960, p < 0.001, respectively), and also between the LNM stromal compartment area and nodal diameter (r = 0.612, p < 0.001), nodal area (r = 0.747, p < 0.001) and LNM area (r = 0.746, p < 0.001), novel insight was that nearly all (98%) LNMs contained stroma, with median TSR-c scores of 35% (IQR 20-60%) and TSR-t of 20% (IQR 10-30%). Moreover, a total of 32 (25%) positive lymph nodes had a diameter of < 5.0 mm. In LNMs, stroma is abundantly present, independent of size, suggesting a role for FAPI PET/CT in improved lymph node detection in CRC.
Identifiants
pubmed: 35482276
doi: 10.1007/s12094-022-02832-9
pii: 10.1007/s12094-022-02832-9
pmc: PMC9338005
doi:
Substances chimiques
Radiopharmaceuticals
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1776-1784Informations de copyright
© 2022. The Author(s).
Références
Eur J Nucl Med Mol Imaging. 2020 Jul;47(8):1820-1832
pubmed: 32222810
Cancers (Basel). 2021 Mar 04;13(5):
pubmed: 33806468
Prz Gastroenterol. 2019;14(2):89-103
pubmed: 31616522
Cancers (Basel). 2021 Mar 19;13(6):
pubmed: 33808627
Clin Radiol. 2010 Sep;65(9):708-19
pubmed: 20696298
Eur J Nucl Med Mol Imaging. 2021 Jan;48(1):73-86
pubmed: 32588089
Eur J Surg Oncol. 2014 Apr;40(4):469-75
pubmed: 24439446
Int J Cancer. 2018 Dec 15;143(12):3194-3200
pubmed: 29978463
Nucl Med Commun. 2012 Nov;33(11):1127-33
pubmed: 23000829
J Exp Med. 2014 Jul 28;211(8):1503-23
pubmed: 25071162
Eur J Nucl Med Mol Imaging. 2022 Apr;49(5):1671-1681
pubmed: 34870727
Clin Transl Radiat Oncol. 2019 Nov 27;20:39-44
pubmed: 31886418
Oncotarget. 2019 Jan 29;10(9):922-923
pubmed: 30847019
Ann Surg Oncol. 2018 Jun;25(6):1454-1455
pubmed: 29616422
Ann Surg Oncol. 1996 Mar;3(2):124-30
pubmed: 8646511
PET Clin. 2021 Jul;16(3):341-351
pubmed: 34053578
Ann Surg Oncol. 2015 May;22(5):1504-12
pubmed: 25395146
Ann Oncol. 2013 Jan;24(1):179-85
pubmed: 22865778
Radiology. 2021 Feb;298(2):393-402
pubmed: 33258746
Histopathology. 2018 Aug;73(2):197-206
pubmed: 29457843
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Cancer Cell. 2018 Mar 12;33(3):463-479.e10
pubmed: 29455927
Eur J Surg Oncol. 2018 Aug;44(8):1241-1246
pubmed: 29739638
Virchows Arch. 2018 Oct;473(4):405-412
pubmed: 30030621
JAMA Surg. 2019 Sep 1;154(9):e192172
pubmed: 31268504
Clin Nucl Med. 2021 Mar 1;46(3):e141-e150
pubmed: 33351507
Int J Cancer. 2021 Sep 1;149(5):1181-1188
pubmed: 34043821
Q J Nucl Med Mol Imaging. 2021 Mar 09;:
pubmed: 33686849
APMIS. 2006 Mar;114(3):201-10
pubmed: 16643187
J Nucl Med. 2020 Sep;61(9):1331-1336
pubmed: 32060216
J Surg Oncol. 1993 Dec;54(4):252-4
pubmed: 8255087
J Nucl Med. 2019 Mar;60(3):386-392
pubmed: 30072500
Cancer Treat Res Commun. 2020;25:100247
pubmed: 33249210
J Nucl Med. 2019 Jun;60(6):801-805
pubmed: 30954939
Mod Pathol. 2012 Oct;25(10):1413-22
pubmed: 22684222
Cell Oncol. 2007;29(5):387-98
pubmed: 17726261
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv263
pubmed: 29741565
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Eur J Cancer. 2011 Feb;47(3):375-82
pubmed: 21036599
Eur J Nucl Med Mol Imaging. 2021 Jun;48(6):1915-1931
pubmed: 33244617
Br J Surg. 2021 Mar 12;108(2):205-213
pubmed: 33711144
Int J Mol Sci. 2012;13(2):1951-2011
pubmed: 22408433
Br J Cancer. 2018 Jul;119(2):164-169
pubmed: 29755119
BMC Cancer. 2019 Mar 29;19(1):284
pubmed: 30922247
Diabetes Obes Metab. 2021 Mar;23(3):692-699
pubmed: 33236523
Eur Radiol. 2018 Apr;28(4):1465-1475
pubmed: 29043428
Nat Commun. 2020 Jan 21;11(1):404
pubmed: 31964880
Front Oncol. 2014 Jan 21;4:1
pubmed: 24478982
J Nucl Med. 2021 Mar;62(3):296-302
pubmed: 33277397
J Surg Oncol. 2018 Apr;117(5):1043-1048
pubmed: 29448309